John Libbey Eurotext

Bulletin du Cancer


Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study Volume 94, issue 3, Mars 2007


See all figures

Laboratoire de biologie médicale, Centre Georges-François-Leclerc, Dijon, Laboratoire de Service d’information médicale, Centre Georges François Leclerc, Dijon, Laboratoire de biologie, Institut Claudius Regaud, Toulouse, Laboratoire de biologie, Centre Henri Becquerel, Rouen, Laboratoire de radioanalyse, Institut Bergonié, Bordeaux, Laboratoire d’oncobiologie, Centre René Gauducheau, Nantes, Laboratoire de biologie clinique, Institut Jean Godinot, Reims, Laboratoire de radioanalyse, Centre Paul Papin, Angers, Laboratoire d’oncobiologie, Centre René Huguenin, Saint-Cloud

This multicentric study was performed in 494 patients with advanced epithelial ovarian cancer in order to assess the predictive and prognostic value of CA125 half-life and CA125 time to normalization during induction chemotherapy in these patients. For 494 stage IIC-IV patients, 397 relapsed (80.4 %) and 382 died (77.3 %) from cancer during follow time (median = 34 months ; range : 3-215 months). In the population of patients with surgical second look (n = 194), CA125 half-life and normalization before the third cycle were significantly related to pathological complete response by univariate (p < 0,0001) and multivariate (p respectively equal to 0,01 and 0.042) studies. CA 125 half-life and time needed for CA125 normalization had an univariate prognostic value for overall survival (OS) (p < 0.0001 for both). In Cox models, CA 125 half-life (p < 0.0001), residual tumour (p = 0.001), CA125 normalization before the third cycle (p = 0.014) and age (p = 0.032) were independent prognostic factors for OS. Conclusion : Among well-established prognostic factors in ovarian cancers, CA 125 half-life and CA125 time to normalization were independent prognostic factors for both achievement of pathological complete response and survival.